BraveCX, an artificial intelligence (AI)-enabled software, reportedly has an area under the curve (AUC) of 98 percent for detecting pneumothorax on chest X-rays.
The Food and Drug Administration (FDA) has granted 510(k) clearance for BraveCX, an emerging triage and notification software for adult chest X-rays, that may facilitate timely diagnosis for urgent cases in an emergency room setting.
BraveCX provides specificity rates ranging between 95 to 97 percent, and areas under the curve (AUC) of 96 percent for pleural effusion and 98 percent for pneumothorax, according to Bering, the developer of BraveCX.
Bering pointed out that findings from a million chest X-rays were utilized to develop the artificial intelligence (AI)-powered software, which was subsequently fine-tuned with over 50,000 labeled chest radiographs from radiologists.
"After over three years of research and collaboration with clinical teams, it's so exciting to see BraveCX emerge as a state-of-the-art tool that has actually 'listened to the end user,’” noted Ignat Drozdov, the CEO and founder of Bering. “FDA clearance means BraveCX prioritizes patient safety (while) still delivering the most advanced risk stratification algorithms where they are needed the most."
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.